Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases - Nature Medicine
- ️Lee, Virginia M Y
- ️Thu Feb 06 2014
Glenner, G.G. & Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890 (1984).
Kosik, K.S., Joachim, C.L. & Selkoe, D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 83, 4044–4048 (1986).
Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. & Goedert, M. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469–6473 (1998).
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).
DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993 (1997).
Bolton, D.C., McKinley, M.P. & Prusiner, S.B. Identification of a protein that purifies with the scrapie prion. Science 218, 1309–1311 (1982).
Ross, C.A. & Poirier, M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 (suppl.), S10–S17 (2004).
Goedert, M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and α-synucleinopathies. Phil. Trans. R. Soc. Lond. B 354, 1101–1118 (1999).
Thorpe, J.R., Tang, H., Atherton, J. & Cairns, N.J. Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J. Neural Transm. 115, 1661–1671 (2008).
Lin, W.L. & Dickson, D.W. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 116, 205–213 (2008).
Lee, S.J., Desplats, P., Sigurdson, C., Tsigelny, I. & Masliah, E. Cell-to-cell transmission of non-prion protein aggregates. Nature reviews. Neurology 6, 702–706 (2010).
Brundin, P., Melki, R. & Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301–307 (2010).
Jucker, M. & Walker, L.C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532–540 (2011).
Aguzzi, A., Sigurdson, C. & Heikenwaelder, M. Molecular mechanisms of prion pathogenesis. Annu. Rev. Pathol. 3, 11–40 (2008).
Volpicelli-Daley, L.A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011).
Luk, K.C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012).
Guo, J.L. & Lee, V.M. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286, 15317–15331 (2011).
Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909–913 (2009).
Iba, M. et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33, 1024–1037 (2013).
Luk, K.C. et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975–986 (2012).
Masuda-Suzukake, M. et al. Prion-like spreading of pathological α-synuclein in brain. Brain 136, 1128–1138 (2013).
Stöhr, J. et al. Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc. Natl. Acad. Sci. USA 109, 11025–11030 (2012).
Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012).
de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685–697 (2012).
Ulusoy, A. et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol. Med. 5, 1051–1059 (2013).
Haass, C. & Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid-β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112 (2007).
Maeda, S. et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856–3861 (2007).
Patterson, K.R. et al. Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286, 23063–23076 (2011).
Lasagna-Reeves, C.A. et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2, 700 (2012).
Silveira, J.R. et al. The most infectious prion protein particles. Nature 437, 257–261 (2005).
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).
Braak, H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249, iii1–iii5 (2002).
Kosaka, K., Tsuchiya, K. & Yoshimura, M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin. Neuropathol. 7, 299–305 (1988).
Thal, D.R., Rub, U., Orantes, M. & Braak, H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).
Brettschneider, J. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20–38 (2013).
Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C. & Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918–934 (2010).
Braak, H. & Del Tredici, K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 121, 589–595 (2011).
Friedhoff, P., Schneider, A., Mandelkow, E.M. & Mandelkow, E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223–10230 (1998).
Wood, S.J. et al. α-synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509–19512 (1999).
Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781–1784 (2006).
Clavaguera, F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. USA 110, 9535–9540 (2013).
Wu, J.W. et al. small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288, 1856–1870 (2013).
Freundt, E.C. et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann. Neurol. 72, 517–524 (2012).
Tapiola, T. et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382–389 (2009).
Mollenhauer, B. et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44–48 (2013).
van Dijk, K.D. et al. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur. J. Neurol. doi:10.1111/ene.12176 (2013).
Yamada, K. et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110–13117 (2011).
Emmanouilidou, E. et al. Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS ONE 6, e22225 (2011).
Emmanouilidou, E. et al. Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838–6851 (2010).
Danzer, K.M. et al. Exosomal cell-to-cell transmission of α-synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
Saman, S. et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842–3849 (2012).
Vella, L.J. et al. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J. Pathol. 211, 582–590 (2007).
Pooler, A.M., Phillips, E.C., Lau, D.H., Noble, W. & Hanger, D.P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389–394 (2013).
Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M. & Diamond, M.I. Trans-cellular propagation of tau aggregation by fibrillar species. J. Biol. Chem. 287, 19440–19451 (2012).
Ren, P.H. et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11, 219–225 (2009).
Münch, C., O'Brien, J. & Bertolotti, A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. USA 108, 3548–3553 (2011).
Frost, B., Jacks, R.L. & Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845–12852 (2009).
Holmes, B.B. et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. USA doi:10.1073/pnas.1301440110 (2013).
Hansen, C. et al. α-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725 (2011).
Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl. Acad. Sci. USA 106, 13010–13015 (2009).
Guo, J.L. & Lee, V.M. Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett. 587, 717–723 (2013).
Gousset, K. et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11, 328–336 (2009).
Dietzschold, B. et al. Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J. Virol. 56, 12–18 (1985).
Cearley, C.N. et al. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16, 1710–1718 (2008).
Cearley, C.N. & Wolfe, J.H. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27, 9928–9940 (2007).
Summerford, C. & Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438–1445 (1998).
Thoulouze, M.I. et al. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol. 72, 7181–7190 (1998).
Weissmann, C., Enari, M., Klohn, P.C., Rossi, D. & Flechsig, E. Transmission of prions. Proc. Natl. Acad. Sci. USA 99 (suppl. 4), 16378–16383 (2002).
Irwin, D.J. et al. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 70, 462–468 (2013).
Brown, P., Gajdusek, D.C., Gibbs, C.J. Jr. & Asher, D.M. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N. Engl. J. Med. 313, 728–731 (1985).
Eisele, Y.S. et al. Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis. Science 330, 980–982 (2010).
Kimberlin, R.H. & Walker, C.A. Pathogenesis of mouse scrapie: effect of route of inoculation on infectivity titres and dose-response curves. J. Comp. Pathol. 88, 39–47 (1978).
Aguzzi, A. & Calella, A.M. Prions: protein aggregation and infectious diseases. Physiol. Rev. 89, 1105–1152 (2009).
Will, R.G. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br. Med. Bull. 66, 255–265 (2003).
Braak, H. & Del Tredici, K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009).
Iwai, A. et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475 (1995).
Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136–144 (1982).
Wang, F., Wang, X., Yuan, C.G. & Ma, J. Generating a prion with bacterially expressed recombinant prion protein. Science 327, 1132–1135 (2010).
Colby, D.W. et al. Design and construction of diverse mammalian prion strains. Proc. Natl. Acad. Sci. USA 106, 20417–20422 (2009).
Makarava, N. et al. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol. 119, 177–187 (2010).
Goedert, M. et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550–553 (1996).
Westaway, D. et al. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 76, 117–129 (1994).
Hsiao, K.K. et al. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc. Natl. Acad. Sci. USA 91, 9126–9130 (1994).
Hill, A.F. & Collinge, J. Subclinical prion infection. Trends Microbiol. 11, 578–584 (2003).
Brandner, S. et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339–343 (1996).
Sandberg, M.K., Al-Doujaily, H., Sharps, B., Clarke, A.R. & Collinge, J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470, 540–542 (2011).
Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T. & Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631–639 (1992).
Roberson, E.D. et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750–754 (2007).
Ittner, L.M. et al. Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 142, 387–397 (2010).
Dahlgren, K.N. et al. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046–32053 (2002).
Lambert, M.P. et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448–6453 (1998).
Walsh, D.M. et al. Naturally secreted oligomers of amyloid-β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
Wang, H.W. et al. Soluble oligomers of β-amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133–140 (2002).
Cohen, S.I. et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. USA 110, 9758–9763 (2013).
Ding, T.T., Lee, S.J., Rochet, J.C. & Lansbury, P.T. Jr. Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209–10217 (2002).
Lashuel, H.A. et al. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089–1102 (2002).
Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194–4199 (2011).
Karpinar, D.P. et al. Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256–3268 (2009).
Tanik, S.A., Schultheiss, C.E., Volpicelli-Daley, L.A., Brunden, K.R. & Lee, V.M. Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288, 15194–15210 (2013).
Wittmann, C.W. et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711–714 (2001).
Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351 (2007).
SantaCruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005).
Aguzzi, A., Heikenwalder, M. & Polymenidou, M. Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8, 552–561 (2007).
Aoyagi, H., Hasegawa, M. & Tamaoka, A. Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. J. Biol. Chem. 282, 20309–20318 (2007).
Yonetani, M. et al. Conversion of wild-type α-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 284, 7940–7950 (2009).
Furukawa, Y., Kaneko, K., Yamanaka, K. & Nukina, N. Mutation-dependent polymorphism of Cu,Zn-superoxide dismutase aggregates in the familial form of amyotrophic lateral sclerosis. J. Biol. Chem. 285, 22221–22231 (2010).
Guo, J.L. et al. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103–117 (2013).
Petkova, A.T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262–265 (2005).
Nekooki-Machida, Y. et al. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. USA 106, 9679–9684 (2009).
Heilbronner, G. et al. Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice. EMBO Rep. 14, 1017–1022 (2013).
Morozova, O.A., March, Z.M., Robinson, A.S. & Colby, D.W. Conformational features of tau fibrils from Alzheimer's disease brain are faithfully propagated by unmodified recombinant protein. Biochemistry 52, 6960–6967 (2013).
Tolnay, M. & Probst, A. The neuropathological spectrum of neurodegenerative tauopathies. IUBMB Life 55, 299–305 (2003).
Dickson, D.W. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol. 246 (suppl. 2), II6–II15 (1999).
Mayeux, R. et al. A population-based investigation of Parkinson's disease with and without dementia—relationship to age and gender. Arch. Neurol. 49, 492–497 (1992).
Morris, J.C., Drazner, M., Fulling, K., Grant, E.A. & Goldring, J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch. Neurol. 46, 651–657 (1989).
Galpern, W.R. & Lang, A.E. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol. 59, 449–458 (2006).
Gidalevitz, T., Ben-Zvi, A., Ho, K.H., Brignull, H.R. & Morimoto, R.I. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 1471–1474 (2006).
Galloway, P.G., Bergeron, C. & Perry, G. The presence of tau distinguishes Lewy bodies of diffuse Lewy body disease from those of idiopathic Parkinson disease. Neurosci. Lett. 100, 6–10 (1989).
Ishizawa, T., Mattila, P., Davies, P., Wang, D. & Dickson, D.W. Colocalization of tau and α-synuclein epitopes in Lewy bodies. J. Neuropathol. Exp. Neurol. 62, 389–397 (2003).
Lu, J.X. et al. Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 1257–1268 (2013).
Korecka, J.A., Verhaagen, J. & Hol, E.M. Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. Regen. Med. 2, 425–446 (2007).
Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. & Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504–506 (2008).
Li, J.Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008).
Schenk, D.B., Seubert, P., Grundman, M. & Black, R. Aβ immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener. Dis. 2, 255–260 (2005).
Banks, W.A. et al. Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23, 2223–2226 (2002).
Couch, J.A. et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 5, 183ra157 (2013).
Caughey, B. & Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267–298 (2003).
Dobson, C.M. Protein folding and misfolding. Nature 426, 884–890 (2003).
Wolynes, P.G., Onuchic, J.N. & Thirumalai, D. Navigating the folding routes. Science 267, 1619–1620 (1995).
Li, J., Browning, S., Mahal, S.P., Oelschlegel, A.M. & Weissmann, C. Darwinian evolution of prions in cell culture. Science 327, 869–872 (2010).
Ghaemmaghami, S. et al. Conformational transformation and selection of synthetic prion strains. J. Mol. Biol. 413, 527–542 (2011).
Nonaka, T., Watanabe, S.T., Iwatsubo, T. & Hasegawa, M. Seeded aggregation and toxicity of α-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 285, 34885–34898 (2010).
Luk, K.C. et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 106, 20051–20056 (2009).
Chen, A.K. et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J. Am. Chem. Soc. 132, 1186–1187 (2010).
Nonaka, T. et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124–134 (2013).